Matthew R. Fleming

Ibrutinib therapy results in atrial fibrillation through modulation of the Src-Erk1/2 pathway

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has revolutionized treatment for B-cell malignancies but increases the incidence of atrial fibrillation (AF) compared to conventional chemotherapy. The downstream signaling pathways through which ibrutinib leads to AF are unk...